行情

TBPH

TBPH

Theravance生物制药
NASDAQ

实时行情|Nasdaq Last Sale

17.84
+0.14
+0.79%
盘后: 17.84 0 0.00% 16:00 11/15 EST
开盘
17.70
昨收
17.70
最高
18.06
最低
17.51
成交量
27.05万
成交额
--
52周最高
29.45
52周最低
15.18
市值
10.13亿
市盈率(TTM)
-4.4551
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

TBPH 新闻

  • 屡破新高美股向上空间或打开 美联储将成为拦路虎?
  • 第一财经.1小时前
  • 消息人士:沙特阿美将不会在美国上市
  • 新浪美股.1小时前
  • 美国零售业遇“寒冬”,TJX为何能独领风骚?
  • 新浪财经-自媒体综合.2小时前
  • 第三季度营收大增28.7%,京东的加速度与下沉路
  • 海外网.3小时前

更多

所属板块

制药
+1.37%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

TBPH 简况

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.
展开

Webull提供Theravance Biopharma Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。